HU206270B - Process for producing pharmaceutical compositions comprising synergic mixtures of interferons and tumour-necrosis factor - Google Patents

Process for producing pharmaceutical compositions comprising synergic mixtures of interferons and tumour-necrosis factor Download PDF

Info

Publication number
HU206270B
HU206270B HU852456A HU245685A HU206270B HU 206270 B HU206270 B HU 206270B HU 852456 A HU852456 A HU 852456A HU 245685 A HU245685 A HU 245685A HU 206270 B HU206270 B HU 206270B
Authority
HU
Hungary
Prior art keywords
interferon
human
ifn
necrosis factor
interferons
Prior art date
Application number
HU852456A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT37891A (en
Inventor
Adolf Guenther
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUT37891A publication Critical patent/HUT37891A/hu
Publication of HU206270B publication Critical patent/HU206270B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU852456A 1984-06-23 1985-06-21 Process for producing pharmaceutical compositions comprising synergic mixtures of interferons and tumour-necrosis factor HU206270B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843423234 DE3423234A1 (de) 1984-06-23 1984-06-23 Synergistische mischungen von interferonen und tumor-nekrose-faktor

Publications (2)

Publication Number Publication Date
HUT37891A HUT37891A (en) 1986-03-28
HU206270B true HU206270B (en) 1992-10-28

Family

ID=6238998

Family Applications (1)

Application Number Title Priority Date Filing Date
HU852456A HU206270B (en) 1984-06-23 1985-06-21 Process for producing pharmaceutical compositions comprising synergic mixtures of interferons and tumour-necrosis factor

Country Status (16)

Country Link
US (1) US4791101A (enExample)
EP (1) EP0170843B1 (enExample)
JP (1) JPS6115842A (enExample)
AT (1) ATE82508T1 (enExample)
AU (2) AU593212B2 (enExample)
CA (1) CA1258426A (enExample)
DD (2) DD238725A5 (enExample)
DE (2) DE3423234A1 (enExample)
DK (1) DK282585A (enExample)
GR (1) GR851492B (enExample)
HU (1) HU206270B (enExample)
IE (1) IE59289B1 (enExample)
IL (1) IL75597A (enExample)
NZ (1) NZ212513A (enExample)
PH (1) PH24406A (enExample)
ZA (1) ZA854682B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
ATE73856T1 (de) * 1984-12-21 1992-04-15 Biogen Inc Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
CA1291706C (en) * 1986-04-03 1991-11-05 Alfred Rudolph COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
ES2034790T3 (es) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0625991B1 (en) * 1992-02-10 1999-04-28 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
EP1416282A3 (en) * 1995-07-25 2004-06-23 Toray Industries, Inc. Method for screening compounds for treating bone disorders
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CZ20022372A3 (cs) * 1999-12-13 2002-11-13 Bioniche Life Sciences Inc. Terapeuticky pouľitelné syntetické oligonukleotidy
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CN1527721A (zh) * 2000-09-12 2004-09-08 基因特罗生物治疗公司 含治疗性蛋白混合物的组合物及其生产方法
US7674453B2 (en) * 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras
CN111239415B (zh) 2013-10-17 2024-03-26 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
EP3455262A4 (en) 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONISTIC ANTI-TUMOR NECROSE FACTOR RECEPTOR SUPER FAMILY ANTIBODIES
CN112105632A (zh) * 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN114436088A (zh) * 2020-11-02 2022-05-06 奥的斯电梯公司 用于电梯轿厢的安全出口组件及电梯系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
JPH0764744B2 (ja) * 1981-11-21 1995-07-12 株式会社林原生物化学研究所 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
ZA844070B (en) * 1983-06-01 1984-12-24 Genentech Inc Gamma interferon-lymphotoxin synergism
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor

Also Published As

Publication number Publication date
ATE82508T1 (de) 1992-12-15
IL75597A0 (en) 1985-10-31
EP0170843B1 (de) 1992-11-19
IE59289B1 (en) 1994-02-09
AU4393185A (en) 1986-01-02
JPS6115842A (ja) 1986-01-23
HUT37891A (en) 1986-03-28
US4791101A (en) 1988-12-13
DD250053A5 (de) 1987-09-30
DK282585A (da) 1985-12-24
CA1258426A (en) 1989-08-15
DD238725A5 (de) 1986-09-03
DE3423234A1 (de) 1986-02-06
NZ212513A (en) 1988-08-30
AU593212B2 (en) 1990-02-08
IL75597A (en) 1991-11-21
IE851547L (en) 1985-12-23
ZA854682B (en) 1987-02-25
EP0170843A1 (de) 1986-02-12
DE3586833D1 (de) 1992-12-24
AU4416785A (en) 1986-01-02
PH24406A (en) 1990-06-13
GR851492B (enExample) 1985-11-25
DK282585D0 (da) 1985-06-21

Similar Documents

Publication Publication Date Title
HU206270B (en) Process for producing pharmaceutical compositions comprising synergic mixtures of interferons and tumour-necrosis factor
Williamson et al. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.
US5928636A (en) Use of IL-12 and IFNα for the treatment of infectious diseases
US5236707A (en) Stabilization of human interferon
EP0233629B1 (en) Compositions for treatement of viral and cancerous skin lesions and the like
US6204022B1 (en) Low-toxicity human interferon-alpha analogs
IL94052A (en) Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines
Weck et al. Antiviral activity of bacteria-derived human alpha interferons against encephalomyocarditis virus infection of mice
EP0131789A2 (en) Composition comprising purified human tumour necrosis factor in conjunction with human interferon and its use
Oleszak et al. Potentiation of the antiviral and anticellular activities of interferons by mixtures of HuIFN-γ and HuIFN-α or HuIFN-β
Kasid et al. Cytokine regulation of tumor necrosis factor-α and-β (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells
WO1999018993A1 (en) Ameliorant for hepatitis c remedial effect and application thereof
JPWO1999018993A1 (ja) Ｃ型肝炎治療効果の改善剤及びその応用
WO2004022088A1 (en) Interferon and immunoglobulin fc fragment hybrid
Samuel et al. Mechanism of interferon action: cloned human leukocyte interferons induce protein kinase and inhibit vesicular stomatitis virus but not reovirus replication in human amnion cells
Oritani et al. Interferon-ζ/limitin: novel type I interferon that displays a narrow range of biological activity
EP0344643B1 (en) Antiviral pharmaceutical composition
US5026544A (en) Methods and compositions for inhibiting the growth of neoplastic cells
JPWO1993011769A1 (ja) 制癌剤
AU643245B2 (en) A pharmaceutical preparation for the maturation of prothymocytes
Carter et al. Independent evolution of antiviral and growth-modulating activities of interferon
JPH11255665A (ja) 低投与量にて腫瘍性または新生組織性細胞増殖を系統的に治療するための組換えヒトγ―インタフェロン含有組成物
Adolf Lymphokines produced by Herpesvirus-transformed marmoset monkey lymphoid cell lines I. Characterization of a constitutively produced interferon
AU706762B2 (en) Interferon tau compositions and methods of use
Koren et al. Macrophage Colony Stimulating Factor (CSF–1) Blocks the Myeloid Suppressive but Not the Antiviral or Antiproliferative Activities of Murine Alpha, Beta, and Gamma Interferons In Vitro